Cite
HARVARD Citation
Lotery, A. et al. (2019). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 395 (10220), pp. 294-303. [Online].